Search academic texts

Information × Registration Number 0224U033595, (0123U101850) , R & D reports Title Determination of the role of molecular genetic predictors in the early diagnosis and prognosis of malignant tumor diseases of the urinary system popup.stage_title Дослідження зв’язку між однонуклеотид-ними поліморфізмами генів довгих некодуючих РНК MALAT1, HOTAIR, ANRIL та виникненням пухлин сечостатевої системи Head Harbuzova Viktoriia Yu., Доктор біологічних наук Registration Date 31-12-2024 Organization Sumy State University popup.description1 The arm of the project is to create a modern tool for predicting the occurrence, assessment of the course and spread of tumors of the urinary system and the appointment of effective treatment based on the study of the relationship of single-nucleotide polymorphism variants of the long non-coding RNA genes MALAT1, HOTAIR and ANRIL, their expression levels and methylation status with the development of tumors kidneys and bladder popup.description2 The obtained results indicate a statistically significant association of the rs1333049 polymorphism in the ANRIL gene with the development of clear cell renal cell carcinoma (CCRCC) under the dominant model (P observed = 0.039). It was found that individuals homozygous for the major allele (G/G) have twice the risk of developing CCRCC compared to carriers of the minor allele (G/C and C/C). After adjusting for age, sex, smoking, and body mass index (BMI), this risk increased to 3.1 times (P adjusted = 0.04). Among women, the risk of CCRCC under the overdominant model for heterozygotes was 2.3 times higher (P observed = 0.037) than in homozygotes, rising to 4.1 times (P adjusted = 0.013) after considering additional factors. The findings have significant practical implications for medicine in Ukraine. Data on the influence of single nucleotide polymorphisms in long non-coding RNA genes (MALAT1, HOTAIR, ANRIL) on the development and metastasis of urinary system tumors can be utilized in the diagnosis and prognosis of these conditions. The identified genetic risk markers are integrated into personalized medicine approaches for screening programs, facilitating early diagnosis, prevention, and more effective treatment. These approaches reduce costs associated with late-stage cancer therapy and improve patients' quality of life Product Description popup.authors Biesiedina Antonina A. Harbuzova Viktoriia Yu. Demenko Maryna M. Kazban Nadiia V. Kryvorotenko Ruslan I. Lebed Liubov P. Lyndin Mykola S. Mykhailichenko Halyna H. Obukhova Olha A. Psariova Valentyna H. Romaniuk Anatolii M. Sikora Yana V. Sokura Victoriia A. Stroi Elizaveta A. Tsepochko Daria H. Shkatula Pavlo Yu. popup.nrat_date 2024-12-31 Close